Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback